GlassScriptPhysician profile
Joseph Daniel Cecil
NPI 1215646377
$6,693.03
in general payments reported to CMS, 2019-2025
24 companies · $2,211 in 2025
The $2,211 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.45 · 2023: $2,038 · 2024: $2,421 · 2025: $2,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,298 · Education: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,297.62 |
| Education | $371.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,161.99 | 2023-2025 | Tremfya |
| Abbvie INC. | $1,045.44 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $579.02 | 2023-2025 | Dupixent, Libtayo |
| Ucb, INC. | $521.34 | 2023-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $453.36 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $415.03 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $358.50 | 2023-2024 | Vtama |
| Amgen INC. | $325.20 | 2023-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $290.89 | 2024-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $276.76 | 2022-2025 | Winlevi, Absorica Ld |
| Genzyme Corporation | $237.69 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $206.57 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $202.66 | 2023-2025 | Adbry |
| Incyte Corporation | $200.44 | 2023-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $73.14 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $73.03 | 2024-2025 | Ycanth |
| Pfizer INC. | $61.63 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $58.57 | 2024 | Acthar |
| Organon LLC | $39.11 | 2023-2025 | Hadlima, Vtama |
| Mylan Institutional INC. | $24.90 | 2023 | Hulio |
| Mayne Pharma Commercial LLC | $24.89 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $24.56 | 2023 | Evusheld |
| Alnylam Pharmaceuticals INC. | $22.35 | 2024 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.96 | 2023 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Cecil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.